Press Release: OncoResponse : OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting 2023 (AACR 2023)
/PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today...
Read full article »
OncoResponse is a Washington-based biotechnology company that researches and develops immunotherapies for the treatment of cancer.
Read more